Kyverna Therapeutics (KYTX) Share-based Compensation (2023 - 2026)

Kyverna Therapeutics' Share-based Compensation history runs 4 years deep, the most recent figure standing at $39.5 million for Q1 2026.

• Quarterly Share-based Compensation rose 19650.0% year-over-year to $39.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.5 million (up 19650.0% YoY) and the FY2025 annual result came in at $22.3 million, down 16.48% from the prior year.
• Share-based Compensation was $39.5 million for Q1 2026 at Kyverna Therapeutics, up from $2.7 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $39.5 million in Q1 2026 and bottomed at $468.0 in Q1 2023.
• A 4-year average of $4.4 million and a median of $1.4 million in 2024 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2024 — Share-based Compensation surged 486652.14% — and 2025, when it sank 91.22%.
• Kyverna Therapeutics' Share-based Compensation stood at $784000.0 in 2023, then jumped by 76.28% to $1.4 million in 2024, then surged by 95.51% to $2.7 million in 2025, then soared by 1361.88% to $39.5 million in 2026.
• Business Quant data shows KYTX's Share-based Compensation at $39.5 million in Q1 2026, $2.7 million in Q4 2025, and $2.7 million in Q3 2025.